Neurotrophins and B-cell malignancies

被引:0
|
作者
Jennifer Hillis
Michael O’Dwyer
Adrienne M. Gorman
机构
[1] National University of Ireland,Apoptosis Research Centre, School of Natural Sciences
[2] University College Hospital,Haematology
来源
关键词
Neurotrophins; Nerve growth factor (NGF); Tropomyosin-related kinase (Trk) receptors; p75; B lymphocytes; B-cell malignancies;
D O I
暂无
中图分类号
学科分类号
摘要
Neurotrophins and their receptors act as important proliferative and pro-survival factors in a variety of cell types. Neurotrophins are produced by multiple cell types in both pro- and mature forms, and can act in an autocrine or paracrine fashion. The p75NTR and Trk receptors can elicit signalling in response to the presence or absence of their corresponding neurotrophin ligands. This signalling, along with neurotrophin and receptor expression, varies between different cell types. Neurotrophins and their receptors have been shown to be expressed by and elicit signalling in B lymphocytes. In general, most neurotrophins are expressed by activated B-cells and memory B-cells. Likewise, the TrkB95 receptor is seen on activated B-cells, while TrkA and p75NTR are expressed by both resting and active B-cells as well as memory B-cells. Nerve growth factor stimulates B-cell proliferation, memory B-cell survival, antibody production and CD40 expression. Brain-derived neurotrophic factor is involved in B-cell maturation in the bone marrow through TrkB95. Overall neurotrophins and their receptors have been shown to be involved in B-cell proliferation, development, differentiation, antibody secretion and survival. As well as expression and activity in healthy B-cells, the neurotrophins and their receptors can contribute to B-cell malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, Burkitt’s lymphoma and multiple myeloma. They are involved in B-cell malignancy survival and potentially in drug resistance.
引用
收藏
页码:41 / 56
页数:15
相关论文
共 50 条
  • [1] Neurotrophins and B-cell malignancies
    Hillis, Jennifer
    O'Dwyer, Michael
    Gorman, Adrienne M.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2016, 73 (01) : 41 - 56
  • [2] Targeting of B-cell receptor signalling in B-cell malignancies
    Jerkeman, M.
    Hallek, M.
    Dreyling, M.
    Thieblemont, C.
    Kimby, E.
    Staudt, L.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2017, 282 (05) : 415 - 428
  • [3] Zanubrutinib in B-cell malignancies
    Das, Manjulika
    [J]. LANCET ONCOLOGY, 2019, 20 (09): : E470 - E470
  • [4] Obinutuzumab for B-cell malignancies
    Owen, Carolyn J.
    Stewart, Douglas A.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1197 - 1205
  • [5] Autoimmunity and B-cell malignancies
    Dighiero, G
    [J]. HEMATOLOGY AND CELL THERAPY, 1998, 40 (01): : 1 - 9
  • [6] B-CELL MALIGNANCIES FREQUENTLY TARGET THE AUTOREACTIVE B-CELL REPERTOIRE
    DIGHIERO, G
    BORCHE, L
    [J]. LEUKEMIA & LYMPHOMA, 1991, 5 : 47 - 51
  • [7] Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
    Choi, Michael Y.
    Kipps, Thomas J.
    [J]. CANCER JOURNAL, 2012, 18 (05): : 404 - 410
  • [8] Somatic hypermutation and B-cell malignancies
    Spencer, J
    Dunn-Walters, DK
    [J]. JOURNAL OF PATHOLOGY, 1999, 187 (02): : 158 - 163
  • [9] Lenalidomide for the treatment of B-cell malignancies
    Chanan-Khan, Asher A.
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1544 - 1552
  • [10] Idelalisib for treatment of B-cell malignancies
    Do, Bryan
    Mace, Morgan
    Rexwinkle, Amber
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (08) : 547 - 555